Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy

Clinical Cancer Research

Volumn 17, Issue 3, 2011, Pages 538-549

  Yang, Sherry W ^a   Cody, James J ^a   Rivera, Angel A ^b,e   Waehler, Reinhard ^c   Wang, Minghui ^b   Kimball, Kristopher J ^d   Alvarez, Ronald A ^d   Siegal, Gene P ^a,c   Douglas, Joanne T ^b,c   Ponnazhagan, Selvarangan ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CONDITIONALLY REPLICATING ADENOVIRUS; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADENOVIRUS 5; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CANCER THERAPY; CANCER TISSUE; CELL KILLING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERAPY EFFECT; TRANSGENE; VIRUS REPLICATION;

ADENOVIRIDAE; CELL LINE, TUMOR; DNA, VIRAL; FEMALE; HUMANS; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; RECEPTORS, CXCR4; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VIRUS REPLICATION;

EID: 79551709763     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1628     Document Type: Article

References (33)

1. Ozols RF, Bookman MA, Connolly DC, et al. Focus on epithelial ovarian cancer. Cancer Cell 2004;5:19-24. (Pubitemid 38121593)
2. Russell WC. Update on adenovirus and its vectors. J Gen Virol 2000;81:2573-604.
3. Krasnykh VN, Douglas JT, van Beusechem VW. Genetic targeting of adenoviral vectors. Mol Ther 2000;1:391-405.
4. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320-3. (Pubitemid 27114163)
5. Kanerva A, Wang M, Bauerschmitz GJ, et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002;5:695-704. (Pubitemid 34619062)
6. Wu H, Seki T, Dmitriev I, et al. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther 2002;13:1647-53. (Pubitemid 35034684)
7. Zhu ZB, Makhija SK, Lu B, et al. Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter. Gene Ther 2004;11:645-8. (Pubitemid 38455983)
8. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000; 19:6642-50. (Pubitemid 32197703)
9. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92. (Pubitemid 34270240)
10. Schmalfeldt B, Prechtel D, Harting K, et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001;7:2396-404.
11. Huang S, Van Arsdall M, Tedjarati S, et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002;94:1134-42. (Pubitemid 34919050)
12. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115:3719-27. (Pubitemid 35203598)
13. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-39. (Pubitemid 36542523)
14. Feldman AL, Stetler-Stevenson WG, Costouros NG, et al. Modulation of tumor-host interactions, angiogenesis, and tumor growth by tissue inhibitor of metalloproteinase 2 via a novel mechanism. Cancer Res 2004;64:4481-6. (Pubitemid 38856919)
15. Oh J, Seo DW, Diaz T, et al. Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res 2004;64:9062-9. (Pubitemid 39665518)
16. Seo DW, Li H, Guedez L, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003;114:171-80. (Pubitemid 36936911)
17. Kirby TO, Rivera A, Rein D, et al. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res 2004;10:8697-703. (Pubitemid 40053439)
18. Olinga P, Groen K, Hof IH, et al. Comparison of five incubation systems for rat liver slices using functional and viability parameters. J Pharmacol Toxicol Methods 1997;38:59-69. (Pubitemid 27515918)
19. Rivera AA, Davydova J, Schierer S, et al. Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells. Gene Ther 2004;11:1694-702. (Pubitemid 39591764)
20. Rocconi RP, Zhu ZB, Stoff-Khalili M, et al. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd). Gynecol Oncol 2007;105:113-21. (Pubitemid 46454332)
21. Baker AH, Wilkinson GW, Hembry RM, Murphy G, Newby AC. Development of recombinant adenoviruses that drive high level expression of the human metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 genes: characterization of their infection into rabbit smooth muscle cells and human MCF-7 adenocarcinoma cells. Matrix Biol 1996;15:383-95. (Pubitemid 27077632)
22. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706-13. (Pubitemid 28520834)
23. Borovjagin AV, Krendelchtchikov A, Ramesh N, Yu DC, Douglas JT, Curiel DT. Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors. Cancer Gene Ther 2005;12:475-86. (Pubitemid 40629338)
24. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996;70:7498-509. (Pubitemid 26339054)
25. Kossakowska AE, Edwards DR, Lee SS, et al. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol 1998;153:1895-902. (Pubitemid 28550676)
26. Rivera AA, Wang M, Suzuki K, et al. Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo. Virology 2004;320:121-34. (Pubitemid 38296719)
27. Bell JC, Lichty B, Stojdl D. Getting oncolytic virus therapies off the ground. Cancer Cell 2003;4:7-11. (Pubitemid 36904156)
28. Hermiston T. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Invest 2000; 105: 1169-72. (Pubitemid 30266066)
29. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998;9:1323-33. (Pubitemid 28312897)
30. Wildner O, Morris JC, Vahanian NN, Ford H Jr, Ramsey WJ, Blaese RM. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther 1999; 6:57-62. (Pubitemid 29043694)
31. Brand K. Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs). Curr Gene Ther 2002;2:255-71.
32. Brand K, Baker AH, Perez-Canto A, et al. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases- 2 into the liver tissue. Cancer Res 2000;60:5723-30.
33. Rigg AS, Lemoine NR. Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo. Cancer Gene Ther 2001;8:869-78. (Pubitemid 33086534)